AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
21 Oct 1999 12:30 PM
RNS
New Proton Pump Inhibitor - Regulatory Application
18 Oct 1999 11:00 AM
RNS
Omeprazole Patent Upheld
08 Oct 1999 03:33 PM
RNS
Notice of Quarterly Rslts
20 Sep 1999 01:30 PM
RNS
Drug Approval
17 Sep 1999 03:52 PM
RNS
Arimidex Data
09 Sep 1999 08:51 AM
RNS
Preliminary Injunctions
31 Aug 1999 04:54 PM
RNS
Interim Dividend Notification
26 Aug 1999 04:00 PM
RNS
Directors' Dealings
23 Aug 1999 08:00 AM
RNS
Prilosec US Patent Cases
19 Aug 1999 09:00 AM
RNS
Injunction Upheld
03 Aug 1999 07:34 AM
RNS
First Interim Dividend
03 Aug 1999 07:33 AM
RNS
Interim Results - Part 3
03 Aug 1999 07:32 AM
RNS
Interim Results - Part 2
03 Aug 1999 07:31 AM
RNS
Interim Results - Part 1
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100